[ad_1]
Mambisa (administered intranasally) and Abdala (intramuscular), created at the Center for Genetic Engineering and Biotechnology in Cuba, are the most recent ‘candidates’ to mitigate the spread of the pandemic and will undergo two phases of tests to demonstrate their effectiveness, he tells Cubavisión, without saying when clinical trials will begin.
“Cuba has four candidate vaccines in clinical trials, one of which appears to be the country’s biotechnology and pharmaceutical industries,” the Cuban Business Group for Biotechnological and Pharmaceutical Industries (BioCubaFarma) tweeted.
At the end of August, Soberana 01 trials began, the first vaccine project against the new coronavirus. The process is still proceeding with no recorded incidents and has the participation of over 700 volunteers.
Unlike other international vaccines whose clinical studies are more advanced and which are produced using inactive adenoviral vectors or viruses, this Cuban drug is based on a recombinant protein.
Soberana 02, on the other hand, is a conjugate vaccine, in which a viral antigen and a tetanus toxoid are combined, which has been tested since 19 October.
Cuba, which has accumulated 8,075 infections since the start of the pandemic and 133 deaths, owns one of the most internationally recognized biotechnology and pharmaceutical industries and currently produces eight vaccines against various diseases, such as meningitis, lung cancer and solid tumors, among others .
Source link
